BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+34.37%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$893M
AUM Growth
+$893M
(+17%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-11.15%
Top 10 Holdings %
Top 10 Hldgs %
49.95%
Holding
59
New
4
Increased
15
Reduced
14
Closed
6
Top Buys
| 1 |
AC Immune
ACIU
|
$26.4M |
| 2 |
Mersana Therapeutics
MRSN
|
$13.2M |
| 3 |
CytomX Therapeutics
CTMX
|
$12.9M |
| 4 |
Replimune Group
REPL
|
$10.8M |
| 5 |
Voyager Therapeutics
VYGR
|
$5.94M |
Top Sells
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$72.5M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
$32.3M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$18.8M |
| 4 |
Xencor
XNCR
|
$18.4M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$11.4M |
Sector Composition
| 1 | Healthcare | 90.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $83.4M | 9.34% | 3,420,562 -1,323,500 | -28% | -$32.3M |
|
2
Merus
MRUS
$4.98B
| $67.1M | 7.51% | 4,539,913 +25,000 | +0.6% | +$369K |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $45.2M | 5.06% | 564,965 -10,002 | -2% | -$801K |
|
4
Kura Oncology
KURA
$686M
| $41.4M | 4.64% | 2,495,156 -280,000 | -10% | -$4.65M |
|
|
FPRX
5
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $41.1M | 4.6% | 3,064,346 +283,000 | +10% | +$3.79M |
|
|
6
AC Immune
ACIU
$205M
| $37.7M | 4.22% | 7,455,534 +5,225,507 | +234% | +$26.4M |
|
7
Arcus Biosciences
RCUS
$1.13B
| $35.1M | 3.93% | 2,810,223 +398,600 | +17% | +$4.98M |
|
|
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $32.8M | 3.67% | 17,426,968 | – | – |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $31.6M | 3.54% | 431,700 -257,151 | -37% | -$18.8M |
|
10
Cytokinetics
CYTK
$4.23B
| $30.8M | 3.44% | 3,801,817 -348,822 | -8% | -$2.82M |
|
|
ARQL
11
DELISTED
Arqule Inc
ARQL
| $30.2M | 3.38% | 6,308,746 +78,328 | +1% | +$375K |
|
|
12
Replimune Group
REPL
$422M
| $24.5M | 2.74% | 1,606,817 +707,200 | +79% | +$10.8M |
|
13
Xoma
XOMA
$392M
| $21.9M | 2.45% | 1,769,029 | – | – |
|
|
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
| $20.8M | 2.33% | 3,579,140 +214,719 | +6% | +$1.25M |
|
|
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $20.5M | 2.3% | 1,400,956 +185,229 | +15% | +$2.71M |
|
|
CALA
16
DELISTED
Calithera Biosciences, Inc
CALA
| $20.4M | 2.28% | 3,023,482 -274,800 | -8% | -$1.85M |
|
|
CCXI
17
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.3M | 2.28% | 1,464,515 -5,223,008 | -78% | -$72.5M |
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $18.2M | 2.04% | 1,788,774 | – | – |
|
|
CNCE
19
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $16.7M | 1.87% | 1,385,487 +235,042 | +20% | +$2.84M |
|
20
AnaptysBio
ANAB
$569M
| $16.1M | 1.8% | 220,265 | – | – |
|
21
Galmed Pharmaceuticals
GLMD
$6.96M
| $15.3M | 1.72% | 1,878,508 | – | – |
|
22
Protagonist Therapeutics
PTGX
$3.67B
| $14.1M | 1.58% | 1,123,255 -516,203 | -31% | -$6.49M |
|
|
PVLA
23
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $13.6M | 1.52% | 4,058,385 -3,399,536 | -46% | -$11.4M |
|
|
24
Mersana Therapeutics
MRSN
$36.5M
| $13.2M | 1.47% | +2,500,000 | New | +$13.2M |
|
|
25
CytomX Therapeutics
CTMX
$336M
| $12.9M | 1.44% | +1,198,000 | New | +$12.9M |
|